Financials
Financial year 2025
Worth noting
- A loss two years in a row.
Gross margin
€ -383,815
▲ 48% vs 2024
Profit
Caution€ -356,083
▲ 57% vs 2024
Debts
Low€ 182,320
▼ 29% vs 2024
Vico Therapeutics International from Zaventem, company number BE0746929395, closed financial year 2025 with a result of € -356,083 after tax. For that financial year Vico Therapeutics International recorded a gross margin of € -383,815 and equity of € 87.7 million. Compared with financial year 2024, the result moved from € -826,353 to € -356,083. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 30, 2026.
What happened at Vico Therapeutics International?
What happened at Vico Therapeutics International in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 356,083. Source: NBB ↗
- Jeroen Vangindertael became a director. NBB
- Joshua Mandel-Brehm became a director. NBB
- Klaus Breiner became a director. NBB
- Felice Isabel van Weegen became a director. NBB
- Primix Bio Ventures became a director. NBB
- Amy Weinfeld Schulman became a director. NBB
- Micah Mackison became a director. NBB
In short
From € 684,636 loss in 2021 to € 356,083 loss in 2025.
A new publication or filing at Vico Therapeutics International? We notify you, reason included.
Follow Vico Therapeutics InternationalNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Behind Vico Therapeutics International are Jeroen Vangindertael, Joshua Mandel-Brehm, Klaus Breiner, Felice Isabel van Weegen, Primix Bio Ventures and Amy Weinfeld Schulman. It owns 100% of Vico Therapeutics US Inc. and 100% of Vico Therapeutics B.V. itself.
Directors
According to the 2025 annual accounts
since 2023
Joshua Mandel-Brehm
Director
since 2023
Klaus Breiner
Director
since 2023
Felice Isabel van Weegen
Director
since 2023
since 2023
Amy Weinfeld Schulman
Director
since 2023
Micah Mackison
Director
since 2023
Martijn Kleijwegt
Director
since 2023
Anders Hinsby
Director
since 2023
Pascal Louis Droller Rémi
Director
since 2023
Establishments
Establishment units
Physical locations of this company
Da Vincilaan 1
1930 Zaventem
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 73 companies are registered at this address.
ALFA LAVAL BENELUX
€ 4.8 million gross margin · 2025
Association of Belgian Travel Organisers
ORTHO - CLINICAL DIAGNOSTICS
€ 12.7 million revenue · 2025
FIRST STOP EUROPE
€ 8 million revenue · 2025
JOMIROU
€ -17,491 gross margin · 2024
+68 more
Details
- Company number
- 0746.929.395
- VAT number
- BE 0746.929.395
- Registered office
- Da Vincilaan 1, 1930 Zaventem
- Names & denominations
- Vico Therapeutics International
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 15 May 2020
- Peppol
- Active · Active since 27 Mar 2026